Primary Progressive Multiple Sclerosis Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

(Albany, USA) "Primary Progressive Multiple Sclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Progressive Multiple Sclerosis Therapeutics Market.
As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Primary Progressive Multiple Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The report provides a detailed description of the Primary Progressive Multiple Sclerosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Primary Progressive Multiple Sclerosis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights of Primary Progressive Multiple Sclerosis Pipeline Report:
• Primary Progressive Multiple Sclerosis key players such as Atara Biotherapeutics, MediciNova, AB Science, and many others involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Different therapeutic candidates are segmented into early-stage, mid-stage, and late-stage of development for the PPMS treatment.
• AB Science has completed the Phase III trial for the efficacy and safety testing of Masitinib to treat patients who had progressive multiple sclerosis in February 2020.
• AB Science presented positive Phase 2b/3 results with masitinib in progressive multiple sclerosis.
• Based on this mechanism of action, masitinib has found its potential to treat several indications in oncology, inflammatory, and neurology diseases. Some of the indications for which masitinib has proven to be revolutionary are Alzheimer's disease, multiple sclerosis, COVID-19, among others.
• On December 13, the FDA granted breakthrough therapy designation to Sanofi's tolebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, for patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). The company noted that regulatory submissions for tolebrutinib are being finalized for the United States and prepared for Europe, with confirmation to follow once a submission has been accepted.
• On 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVOTM (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.
• In September 2024, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus ZunovoTM (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.

Primary Progressive Multiple Sclerosis Overview
Primary Progressive Multiple Sclerosis (PPMS) is a less common form of multiple sclerosis (MS), affecting approximately 10-15% of MS patients. Unlike relapsing-remitting MS (RRMS), which involves distinct flare-ups and remissions, PPMS is characterized by a gradual worsening of neurological function from the onset, without early relapses or remissions.
PPMS results from immune system attacks on the central nervous system (CNS), leading to inflammation, demyelination (damage to the protective myelin sheath around nerves), and nerve degeneration. Symptoms typically include progressive muscle weakness, difficulty walking, balance problems, spasticity, and cognitive changes. The progression rate varies among individuals, but disability tends to accumulate more quickly compared to RRMS.
Diagnosing PPMS can be challenging, often requiring MRI scans, cerebrospinal fluid analysis, and clinical assessments. There is no cure for PPMS, but disease-modifying therapies like ocrelizumab (the first FDA-approved treatment for PPMS) can slow progression. Symptom management includes physical therapy, mobility aids, and medications for spasticity and pain.
Research continues to explore new treatments targeting neuroprotection and remyelination. Early diagnosis and comprehensive management can help improve the quality of life for individuals with PPMS.

Learn More about the Clinical and Commercial Development Activities in the Primary Progressive Multiple Sclerosis Therapeutics Domain @
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Primary Progressive Multiple Sclerosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Primary Progressive Multiple Sclerosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Progressive Multiple Sclerosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Primary Progressive Multiple Sclerosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Primary Progressive Multiple Sclerosis treatment market.

Primary Progressive Multiple Sclerosis Therapeutics Analysis
Around 10+ noteworthy pharma and biotech companies are actively involved in the development of therapies for Primary Progressive Multiple Sclerosis (PPMS). Among these, certain companies stand out due to their advancement in the development pipeline, particularly in the most advanced stage-Phase III clinical trials.

Primary Progressive Multiple Sclerosis Companies in the Therapeutics Market Include:
• Atara Biotherapeutics
• AB Science
• Sanofi
• Medici Nova
• MedDay Pharma
• Roche
• Mapi Pharma
• Brainstorm-Cell Therapeutics
And Many Others

Emerging and Marketed Primary Progressive Multiple Sclerosis Therapies Covered in the Report Include:
• Tolebrutinib: Sanofi
• ATA 188: Atara Biotherapeutics
• Masitinib: AB Science
And Many More

Get an in-depth Assessment of the Emerging Therapies and Primary Progressive Multiple Sclerosis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Primary Progressive Multiple Sclerosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Primary Progressive Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Primary Progressive Multiple Sclerosis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Primary Progressive Multiple Sclerosis Current Treatment Patterns
4. Primary Progressive Multiple Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Progressive Multiple Sclerosis Late-Stage Products (Phase-III)
7. Primary Progressive Multiple Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Progressive Multiple Sclerosis Discontinued Products
13. Primary Progressive Multiple Sclerosis Product Profiles
14. Primary Progressive Multiple Sclerosis Companies
15. Primary Progressive Multiple Sclerosis Drugs
16. Dormant and Discontinued Products
17. Primary Progressive Multiple Sclerosis Unmet Needs
18. Primary Progressive Multiple Sclerosis Future Perspectives
19. Primary Progressive Multiple Sclerosis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Neuroprosthetics Market: https://www.delveinsight.com/report-store/neuroprosthetics-market-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Acrocallosal Syndrome Market: https://www.delveinsight.com/sample-request/acrocallosal-syndrome-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Molecular Glue Trials: https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/myocardial-infarction-market
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Healthcare Consulting: https://www.delveinsight.com/consulting
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/business-development-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.